GDRX · Goodrx Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $796.85M | $792.32M | $750.26M | $766.55M | $745.42M | $550.70M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $121.03M | $123.75M | $135.84M | $143.14M | $125.86M | $61.82M |
| SG&A | $113.96M | $117.86M | $125.52M | $144.79M | $154.69M | $461.45M |
| Total Operating Expenses | $709.36M | $726.48M | $777.27M | $764.82M | $732.02M | $826.42M |
| D&A | $85.22M | $69.54M | $107.67M | $54.18M | $34.54M | $18.43M |
| Operating Income | $87.49M | $65.85M | ($27.01M) | $1.74M | $13.41M | ($275.72M) |
| Interest Expense | $42.60M | $52.92M | $56.73M | $34.24M | $23.64M | $27.91M |
| Income Tax | $26.10M | $15.07M | ($46.70M) | $9.60M | $15.08M | ($9.83M) |
| Net Income | $30.44M | $16.39M | ($8.87M) | ($32.83M) | ($25.25M) | ($293.62M) |
| EPS - Basic | $0.09 | $0.04 | ($0.02) | ($0.08) | ($0.06) | ($1.07) |
| EPS - Diluted | $0.09 | $0.04 | ($0.02) | ($0.08) | ($0.06) | ($1.07) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $261.82M | $448.35M | $672.30M | $757.16M | $941.11M | $34.60M |
| Accounts Receivable | $235.75M | $145.93M | $143.61M | $117.14M | $118.08M | $68.73M |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $19.41M | $14.14M | $36.27M | $17.70M | $17.50M | $10.29M |
| Current Assets | $643.10M | $659.25M | $872.79M | $919.69M | $1.09B | $1.09B |
| Total Assets | $1.40B | $1.39B | $1.59B | $1.60B | $1.61B | $1.47B |
| Current Liabilities | $246.00M | $123.90M | $122.56M | $76.32M | $81.11M | $59.55M |
| Long-term Debt | $483.26M | $486.71M | $647.70M | $651.80M | $655.86M | $659.89M |
| Total Liabilities | $787.80M | $663.41M | $826.84M | $789.80M | $775.95M | $758.75M |
| Stockholders' Equity | $616.26M | $724.66M | $761.96M | $814.83M | $831.68M | ($31.75M) |
| Retained Earnings | ($1.41B) | ($1.44B) | ($1.46B) | ($1.45B) | ($1.42B) | ($1.39B) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $167.90M | $183.89M | $138.29M | $146.78M | $178.78M | $131.34M |
| Investing Cash Flow | ($119.96M) | ($70.35M) | ($55.77M) | ($210.50M) | ($178.73M) | ($91.62M) |
| Financing Cash Flow | ($234.47M) | ($337.50M) | ($167.40M) | ($120.23M) | ($30.53M) | $905.82M |
| CapEx | $3.52M | $1.24M | $1.04M | $3.97M | $4.57M | $20.55M |
| Free Cash Flow | $164.38M | $182.65M | $137.25M | $142.81M | $174.21M | $110.79M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | 11.0% | 8.3% | -3.6% | 0.2% | 1.8% | -50.1% |
| EBITDA margin | 21.7% | 17.1% | 10.8% | 7.3% | 6.4% | -46.7% |
| Net margin | 3.8% | 2.1% | -1.2% | -4.3% | -3.4% | -53.3% |
| Free cash flow margin | 20.6% | 23.1% | 18.3% | 18.6% | 23.4% | 20.1% |
| FCF / Net income | 5.40 | 11.14 | -15.48 | -4.35 | -6.90 | -0.38 |
| R&D / Revenue | 15.2% | 15.6% | 18.1% | 18.7% | 16.9% | 11.2% |
| SG&A / Revenue | 14.3% | 14.9% | 16.7% | 18.9% | 20.8% | 83.8% |
| Effective tax rate | 46.2% | 47.9% | - | - | - | - |
| Return on assets | 2.2% | 1.2% | -0.6% | -2.0% | -1.6% | -20.0% |
| Return on equity | 4.9% | 2.3% | -1.2% | -4.0% | -3.0% | 924.7% |
| Return on invested capital | 4.3% | 2.8% | -1.5% | 0.1% | 0.7% | -34.7% |
| Liquidity | ||||||
| Current ratio | 2.61 | 5.32 | 7.12 | 12.05 | 13.42 | 18.24 |
| Quick ratio | 2.61 | 5.32 | 7.12 | 12.05 | 13.42 | 18.24 |
| Cash ratio | 1.06 | 3.62 | 5.49 | 9.92 | 11.60 | 0.58 |
| Leverage | ||||||
| Debt / Equity | 0.78 | 0.67 | 0.85 | 0.80 | 0.79 | -20.78 |
| Debt / Assets | 0.34 | 0.35 | 0.41 | 0.41 | 0.41 | 0.45 |
| Debt / EBITDA | 2.80 | 3.60 | 8.03 | 11.66 | 13.68 | - |
| Interest coverage | 2.1x | 1.2x | -0.5x | 0.1x | 0.6x | -9.9x |
| Equity multiplier | 2.28 | 1.92 | 2.09 | 1.97 | 1.93 | -46.30 |
| Liabilities / Assets | 0.56 | 0.48 | 0.52 | 0.49 | 0.48 | 0.52 |
| Efficiency | ||||||
| Asset turnover | 0.57 | 0.57 | 0.47 | 0.48 | 0.46 | 0.37 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 108d | 67d | 70d | 56d | 58d | 46d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | 30.1x | 116.3x | - | - | - | - |
| P / B | 1.6x | 2.5x | 3.6x | 2.4x | 16.1x | - |
| P / S | 1.2x | 2.3x | 3.7x | 2.5x | 18.0x | 20.1x |
| EV / EBITDA | 6.9x | 13.8x | 33.8x | 32.5x | 273.5x | - |
| Growth | ||||||
| Revenue growth (YoY) | 0.6% | 5.6% | -2.1% | 2.8% | 35.4% | - |
| Revenue CAGR (3y) | 1.3% | 2.1% | 10.9% | - | - | - |
| Revenue CAGR (5y) | 7.7% | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 32.9% | - | - | -87.0% | - | - |
| Net income growth (YoY) | 85.7% | - | 73.0% | -30.0% | 91.4% | - |
| EPS growth (YoY) | 125.0% | - | 75.0% | -33.3% | 94.4% | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -10.0% | 33.1% | -3.9% | -18.0% | 57.2% | - |
| FCF CAGR (5y) | 8.2% | - | - | - | - | - |
| Book value growth (YoY) | -15.0% | -4.9% | -6.5% | -2.0% | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$796.85M totalPrescription Transactions Revenue$544.00M · 68.3%
Pharma Direct Revenue$151.38M · 19.0%
Subscription Revenue$83.79M · 10.5%
Other Revenue$17.69M · 2.2%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
0.44
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
6/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Services-Computer Processing & Data Preparation
Comparing GoodRx Holdings against the 5 most active filers in the same SIC group.